Population (n)	Main results	Author
PM (n=363) DM (n=654) (Chinese population)	<ul> <li>Only rs3733197 resulted significantly associated to DM +PM</li> <li>Only rs3733197 resulted significantly associated with DM and PM/DM patients with ILD involvement</li> </ul>	Chen <i>et al</i> . (1)
PM (n=88) and DM (n=63) vs. HC (n=116) Vietnamese pts	HLA- DRB*13 was significantly associated to risk of PM development but not to DM. HLA-DRB1*09 was protective for DM.	Nguyen et al. (2)
IIMs (n=74) pts (58 DM, 16 PM) HC (n=22), SLE pts (n=20), SSc pts (n=20), RA pts (n=20)	- PMN elastase was significantly higher in IIMs compared to HC - PMN elastase was significantly higher in IIMs with high disease activity	Wu S. et al. (4)
IIMs complicated by ILD (n=30) vs. HC (n=30) vs. pulmonary infection (n=30)	- Serum MCP-1 and TGF- $\beta$ 1 levels were significantly higher in PM/DM pts compared to HC and to pulmonary infection group.	Wu C.Y. et al. (5)
IIMs (n=110: 40 DM, 40 PM, 30 CAM) vs. HC (n=42).	<ul> <li>S100A11 was detectable in cytoplasm of necrotising and regenerating myofibres.</li> <li>Plasmatic S100A11 was significantly higher IIMs compared to HC</li> </ul>	Cerezo <i>et al.</i> (6)
IIMs (n=148; 109 DM, 39 PM, 28 anti-Jo1 positive, 52 anti-MDA5 positive and 68 antibodies negative) vs. 56 HC	<ul> <li>MMP9 mRNA levels in PBMCs was significant higher in IIMs pts compared to HC</li> <li>MMP9 mRNA levels are similar in anti-Jo1, anti-MDA5 and antibodies negative pts compared to HC</li> <li>MMP9 serum level was not significantly different between IIMs and and between patient groups with and without ILD</li> <li>MMP9 serum level was significantly higher in anti-Jo1 positive pts compared to anti-MDA5 positive, antibody-negative, and HC -In anti Jo1 positive MMP9 was more released from isolated neutrophils than from isolated PBMCs</li> </ul>	Liu <i>et al.</i> (7)
IIMs (n=119: 39 DM, 49 IMNM, 18 ASSD, 13 IBM) vs. HC (n=20)	<ul> <li>The IFN1 inducible gene are markedly elevated in DM, moderately expressed in ASSD and minimally expressed in IBM and IMNM.</li> <li>The IFN2 specific genes are increased in IBM, ASSD, and DM biopsies compared to HC.</li> <li>IFN2 inducible genes are much lower in IMNM compared to HC and other IIM (DM; IBM and ASS)</li> <li>IFN1 and IFN2inducible gene had a positive correlation with gene associated to inflammatory cells (T-cells and macrophages) and to muscle regeneration</li> <li>Higher level of IFN inducible gene correlate with higher CK level and decreased muscle strength</li> </ul>	Pinal- Fernandez <i>et al.</i> (8)
IIMs (n=47: 32 DM, 13 PM and 3 ASSD)	<ul> <li>DM patients had significantly higher IFN1 signatures compared to other IIMs.</li> <li>MDA5 positive pts had highest IFN1 signature compared to ARS group and double negative pts</li> <li>No significative difference was found in pts with ILD.</li> </ul>	Ono <i>et al</i> . (9)
DM patients with anti-NXP-2 (n=13) vs. DM with anti-MDA5 (n=6), DM with anti-Mi2 (n=7) and HC (n=11).	<ul> <li>Anti-NPX-2 pts showed vasculopathy of perimysial arterioles</li> <li>MxA was expressed in endothelial cells, smooth muscle cells and pericytes of the diseased arterioles.</li> <li>VEGF was low in endomysial neovessels</li> </ul>	Liu et al. (11)
IMNM (n=10), DM (n=10), ASSD (n=10), IBM (n=9) and HC (n=10)	<ul> <li>- ISG15 expression was higher in muscle sample from DM pts compared to IMNM, ASSD and IBM</li> <li>- Gene expression induced by IFNγ was high in ASSD and IBM, low in DM and absent in IMNM:</li> <li>1) Immunohistochemical distribution of IFNγ inducible MHC-2 was perifascicular in ASSD and IBM compared with IMNM and DM</li> <li>2) CIITA gene was higher in ASSD and IBM compared with IMNM and DM</li> <li>3) HLA-DOB was significantly higher in IBM and in ASSD</li> <li>4) HLA-DPB was significantly higher in IBM and ASSD both compared to IMNM.</li> <li>5) HLA-DPB gene was significantly higher in IBM and ASSD both compared to DM.</li> <li>7) GBP2 gene was significantly higher in IBM and ASSD</li> <li>8) GBP2 gene was significantly higher in ASSD</li> </ul>	Rigolet <i>et al</i> . (10)
71 pts (PM n= 10 and DM n=61) vs. HC (n=30)	<ul> <li>CD3+T and CD4+T are markedly decreased in PM and DM compared to HC.</li> <li>In DM CD8+T and NK cells are significantly reduced compared to HC.</li> <li>B cells are significantly reduced in PM compared to HC.</li> <li>Treg cells and Th1 cells were significant lower both in PM and DM compared to HC</li> <li>Th17/Treg in PM/DM are significantly higher than that in HCs</li> <li>sIL-2Rα is higher in PM/DM compared to HC</li> <li>IL-2 level in PM/DM is significantly lower than HC</li> <li>Other cytokines are higher in PM/DM than HC: IL-4 (only in DM), IL-6, IL-10, TNF-α (only in DM), IFN-γ and IL-17</li> <li>In DM pts treated with Id-IL-2 the number of Tregs is significantly upregulated.</li> <li>Disease activity (MYOACT) was negatively correlated to T cell, IL-2 levels, ESR, CRP and positively correlated to B cells percentage and muscle enzymes level.</li> <li>Tregs deficiency was an independent risk factor for ILD</li> </ul>	Feng <i>et al</i> . (13)
44 pts (11 PM and 33 DM) vs. 20 HC	<ul> <li>mTRAIL signal was weak in HC and strong in muscle tissue from PM and DM pts (primarily located in the infiltrated mononuclear cells)</li> <li>Serum TRAIL (s TRAIL) was significantly higher in PM pts and DM pts compared to HC</li> <li>mTRAIL and its receptors, including DR4 and DR5, was significantly elevated on circulating T cells from PM and DM pts than HC.</li> <li>sTRAIL positively correlate with disease activity scoring by MYOACT tool, with dysphagia and Jol positivity.</li> <li>sTRAIL decrease after 3 to 6 months of therapy.</li> </ul>	Zhou <i>et al</i> . (14)

## Supplementary Table S1. Summary of main results of studies exploring IIMs pathogenesis.

## One year in review: idiopathic inflammatory myopathies / G. Zanframundo et al.

Population (n)	Main results	Author
IIMs pts (n=47) vs. HC (n=30)	<ul> <li>- CD4+CXCR5+CCR7<sup>Io</sup>PD-1<sup>Ini</sup>T cells was significantly increased in IIMs compared to HC</li> <li>- High levels of CD4+CXCR5+CCR7<sup>Io</sup>PD-1<sup>Ini</sup>T cells was found in pts with anti-NPX2 positivity antibodies, while low levels were found in pts who were positive for anti-TIFγ and anti-HMGCR</li> <li>- Intracellular IL-21 expression was significantly more frequent in CD4+CXCR5+CCR7IoPD-</li> </ul>	Zhanget al. (15)
	<ul> <li>1hi T cells from IIMs pts compared to HC</li> <li>- IL-21 and CD4+CXCR5+CCR7loPD-1hi T cells positively correlate with disease activity and reduced after 6 months of therapy</li> </ul>	
IIMs-ILD (n= 85: 17 PM-ILD, 25 DM-ILD and 43 ADM-ILD); IIMs without ILD (n= 19: 4 PM, 8 DM and 7 ADM); patients with RA-ILD (n=14), patients with SSC-ILD (n=7), patients with idiopathic pulmonary fibrosis (n= 6), patients with community acquired pneumonia (n=7), and HC (n=13)	<ul> <li>CD4+CXCR4+ T cells is increased among PBMCs and BALF in IIMs-ILD patients compared with disease controls and HCSerum KL-6 concentrations were also elevated in IIMs-ILD patients compared with HC but it should be not considered specific, being observed also in disease controls.</li> <li>SDF-1 was elevated in the serum of IIMs-ILD patients compared with other controls</li> <li>The peripheral percentage of CD4+CXCR4+ T cells was significantly correlated with the extent of structural changes, as identified by HRCT score and reduction of FVC and DLCO</li> <li>Pts with high CD4+CXCR4+ (&gt;30%) tend to have negative prognostic factors as baseline high HRCT score, low FVC%, higher ferritin levels, presence of anti-MDA5 and ADM phenotype.</li> <li>CD4+CXCR4+ T cells (&gt;30%) was an independent risk factors for mortality and decrease among survivors within the first month after treatments</li> </ul>	Wang <i>et al</i> . (16)
IIMs/ASSD pts (n=24) vs. sarcoidosis pts (n=7) and HC (n=12)	<ul> <li>In BALF:</li> <li>CD4+T response to HisRS- protein was found in 3/4 pts; response to HisRS11-23 was found 2/3 IIMs/ASSD (median CD40L fold-change: 88; 27-149).</li> <li>In PBMCs:</li> <li>CD4+T response to HisRS-protein was found in 14/18 IIMs/ASSD; response to HisRS11-23 was found in 11/14 IIMs/ASSD</li> <li>CD4+T response to HisRS11-23 was found in 3/7 sarcoidosis, and in 5/12 HCs</li> <li>Number of CD4+CD40L+T cells that produced in FNγ was significantly higher from BALF compared to cells isolated from blood both after stimulation of HisRS and HisRS11-23</li> <li>Anti-Jo1 autoantibodies were detected in BALF in 6/7 anti-Jo1+ patients, in 2/9 sarcoidosis and not detected in anti-Jo1- pts and HC</li> </ul>	Galindo-Feria et al. (17)
DM (n=13) vs. HC (n=18)	<ul> <li>DM pts had higher proportion of naïve CD4+Tcells and lower CD4+ TEM-cell than HC.</li> <li>DM pts had lower proportion of naïve CD8+ T and CD8+ TCM-cell.</li> <li>Treg-cell, Th1 and Tfh-cell proportions were lower in pts.</li> <li>Th2 and Th17 are similar between DM and HC.</li> <li>DM pts had higher proportion of naïve B-cell and lower proportion of memory B-cell.</li> <li>Presence of ILD contributed to the differences between DM and HC.</li> <li>After treatment there was no change in proportion of T-cells while there was an increase of memory B-cell.</li> </ul>	Sasaki <i>et al</i> . (18)
<ul> <li>IBM (n= 40); other IIMs (n=77); mitochondrial non-inflammatory myopathy (n=188); HC (n=106).</li> <li>-IBM n=10 in cohort 1 and n=8 in cohort 2.</li> <li>-16 HC (8 subject matched for age and sex with each IBM cohort).</li> <li>-ASSD Jo1 positive n =10,</li> <li>-anti-HMGCR IMNM, n=9</li> <li>- anti-SRP IMNM, n=7</li> </ul>	<ul> <li>Muscle gene expression demonstrate an increased cytotoxic lymphocyte signature in IBM distinct from all other muscle diseases.</li> <li>Abundance of T cell-related chemokines and cytokines, in particular IFNG and its induced chemokines and cytokines CXCL9, CL5, and IL32 was present</li> <li>High differentiated CD8+cytotoxic T cell are high represented in IBM muscle (more than in PM)</li> <li>CD8T-bet+ are significantly more frequent in IBM patients compared to healthy donors.</li> <li>CD8+ terminally differentiated memory T cells ((CD8+ CD45RA+ CCR7) are significantly more frequent in IBM pts compared to HC</li> <li>Marked increase in the expression of CD57 within CD8T-bet+ cells in IBM pts compared to HC, in both CD8T-bet+ cells and CD8T-bet- cells</li> <li>CD8T-bet+ CD57+ cells are CD28null CD27null CD127null in both pts and HC</li> <li>Decrease in expression of CD28, CD27 and CD127 (both in pts and HC)</li> </ul>	Greenberg <i>et al.</i> (19) Dzangue- Tchoupou <i>et al.</i> (20)
IBM (n=10) vs. HC (n=10)	- TDP-43 was increased in IBM compared to HC and colocalised with mitochondria	Huntley et al. (21)
IBM (n=11) vs. controls (n=11: 2 PM, 3 DM 1 spinobulbar muscular atrophy, 1 progressive muscular atrophy, 1 amyotrophic lateral sclerosis and 3 HC)	CYLD expression in degenerative myofibres of IBM	Yamashita <i>et al.</i> (22)
PM/DM (n=24) vs. HC (n=12) Animal models: of EAM (n=6) vs. control (n=6)	<ul> <li>CD163 was increased in PM/DM muscle samples while no expressed in HC.</li> <li>Muscle mRNA levels of MCP-1, TNF-α, IL-6 were increased in pts compared to HC</li> <li>Muscle mRNA levels of Nef2 was reduced in pts compared to HC</li> <li>Serum CK, ROS and pro-inflammatory factors (MCP-1, TNF-α, IL-6) were significantly higher in pts compared to HC.</li> <li>Macrophages isolated from EAM transfected by Nrf2 showed:</li> <li>significant decrease of the mRNA and protein levels of MCP-1, TNF-α, IL-6</li> <li>promotion of mRNA and protein levels of total Nrf2 and of antioxidant protein.</li> <li>significant reduction of migration ability</li> </ul>	Liu <i>et al</i> . (24)

PM: polymyositis; DM: dermatomyositis; HC: healthy controls; pts: patients; SNP: single nucleotide polymorphism; BANK1B: cell scaffold protein with ankyrin repeats 1 BANK1; IIMs: idiopathic inflammatory myopathies; OR: odds ratio; PMN: polymorphonuclear; ENR: elastase-to-neutrophil ratio; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SSc: systemic sclerosis; CAM: cancer associated myositis: MYOACT: myositis disease activity assessment; MMP9: matrix metalloproteinases-9; ASSD: antisynthetase syndrome; IBM: inclusion body myositis; IMNM: immune mediated necrotising myopathy; IFN: interferon; IFN1: type I interferon; IFN2: type II interferon; CK: creatine kinase; MDA5: melanoma differentiation-associated protein 5; ARS: antibodies to T-RNA synthetase; NPX2: nuclear matrix protein 2; BALF: bronchoalveolar lavage fluid; KL-6: Krebs von den Lungen-6; SDF-1: stromal cell derived factor-1; MCP-1: monocyte chemoattractant protein-1; TGF- $\beta$ I: transforming growth factor- $\beta$ I; ASSD: anti-synthetase syndrome; IBMCs: peripheral blood mononuclear cells; CyTOF: cytometry by time of flight; MMI: median mass intensities; IL-: interleukin; TNF- $\alpha$ : tumour necrosis factor- $\alpha$ ; IFN- $\gamma$ : interferon- $\gamma$ ; sIL- $2R\alpha$ : soluble interleukin-2 receptor  $\alpha$ ; Id-IL-2: low-dose IL-2; CYLD: cylindromatosis; MXA: myxovirus resistance protein A; VEGF: vascular endothelial growth factor; EAM: experimental autoimmune myositis; CK: creatine kinase; ROS: reactive oxygen species; MCP-1: mast cell protease-1; TCM: central memory T; TEM: effector memory T; T1-IFN: type 1 interferon.